Visual Field Analysis With Artificial Intelligence

Condition(s) studied

Investigational drug(s) / intervention(s)

Visual Field Perimeter Optimized with Eye Gaze Capture and Artificial Intelligence: 1. Natural Eye Movement To the best of our knowledge, this is the first visual field perimeter software that allows users to move their eyes naturally during the test. Previous visual field tests required that patients maintain a central gaze throughout the test as test points flashed in the periphery of their vision; our test allows patients to look directly at these test points. 2. Simplified Data Capture To the best of our knowledge, this is the first visual field perimeter software that reliably eliminates the need for a hand-held clicker to register test points as the user sees them. 3. Attention Monitoring In previous tests, staring at a central spot could induce sleepiness and inattention; our test employs a software monitor that pauses the test, gives encouragement when appropriate, and allows the patient to regain focus. This allows for far greater accuracy in data reporting. 4. Artificial Intelligence (AI) Our test uses AI to optimize the test parameters.

Study summary

The purpose of this study is to analyze visual field data from healthy participants. This data will be used to develop and optimize a new visual field perimeter test. The test will incorporate an advanced algorithm, which may include the use of Artificial Intelligence (AI), to enhance accuracy and efficiency in identifying test points.

Eligibility

Primary outcome measure(s)

• Brightness Threshold — Within a 10 minute test
  At each position of the peripheral visual field, a healthy individual's ability to see a test point will be measured. The brightness (measured in apostilbs) along a logarithmic scale (0.1 dB to 1000 dB) will be adjusted and the threshold will be defined as a brightness at which the healthy individual can see that test point \> 50% of the time.
• Duration Threshold — Within a 10 minute test
  At each position of the peripheral visual field, a healthy individual's ability to see a test point will be measured. The duration (measured in seconds) will be adjusted and the threshold will be defined as the time at which the healthy individual can see that test point \> 50% of the time.

Trial sites (1)

Other trials for the same condition